Is the Ramsay Health Care share price in the buy zone?

Is it time for investors to buy Ramsay Health Care Limited (ASX: RHC) with the share price just below its 52-week high?

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Ramsay Health Care Limited (ASX: RHC) share price has been a strong performer over the last several weeks. Shares in the private hospital operator have risen 11% to $72.30 since the Federal election on 18 May, despite no market sensitive announcement being released since March.

Prior to the election, the Labor Party had announced a policy of putting a 2% cap on premium increases by private health insurers, which was priced into Ramsay's share price.

There were concerns that private health insurers would place additional pressure on private hospital operators such as Ramsay to lower prices in order to compensate for the capped premium increases. This would have materially impacted Ramsay's margins and future profitability. 

The election result has seen a reversal of fortunes in the sector, as business is expected to continue as usual moving forward. Similarly, investors have also become bullish on private health insurers such as Medibank Private Ltd (ASX: MPL) and NIB Holdings Limited (ASX: NHF), which have seen their share prices rise 20% and 32%, respectively, since the Federal election. 

Is this a return to double-digit earnings growth? 

Ramsay has guided for a soft FY19 by its own standards with management reaffirming core earnings per share growth of up to 2% including the Capio acquisition in February. The purchase of Capio is expected to be dilutive to earnings in FY19 and accretive within 2 or 3 years as Ramsay focuses on achieving synergies from the acquisition. 

The market is currently pricing in an acceleration in earnings growth for FY20, with the current earnings per share consensus for FY20 at $3.16. This would represent earnings growth of around 10% over the current FY19 consensus forecast of $2.87, and a return to the double-digit earnings growth that the company has delivered on a relatively consistent basis over the last decade. 

Foolish takeaway

For long-term shareholders, demand from the ageing population is expected to drive growth in the sector and Ramsay continues to maintain a market-leading position in Australia, which remains the largest contributor to group profitability. 

However, at 23 times forward earnings, shares in Ramsay are not cheap and a lot of bullishness is baked in at current prices. As a result, I would view Ramsay as a hold and would wait until the company updates the market on its expectations for FY20 before reassessing. 

Motley Fool contributor Tim Katavic owns shares of Ramsay Health Care Limited. The Motley Fool Australia has recommended NIB Holdings Limited and Ramsay Health Care Limited. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Male doctor in a lab coat working at laptop looking serious.
Healthcare Shares

This bombshell for ASX healthcare shares could hit 6 million Australians

This could have a large impact.

Read more »

Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.
Healthcare Shares

2 ASX healthcare shares having a stellar run today

The ASX healthcare sector is down today but these two stocks are bucking the trend.

Read more »

A company manager presents the ASX company earnings report to shareholders at an AGM.
Healthcare Shares

Why this $13 billion ASX 200 healthcare stock is surging today

A change in sentiment for the healthcare player.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

This ASX 200 stock hit a 52-week low and a top broker thinks it can rebound

Patient investors may see this stock make a pleasing recovery.

Read more »

A couple smile as they look at a pregnancy test.
Healthcare Shares

Why this sold-off ASX healthcare share could be an exciting dividend buy

This could be a healthy stock for dividends.

Read more »

a smiling woman sits at her computer at home with a coffee alongside her, as if pleased with her investments.
Healthcare Shares

Is CSL the best ASX 100 share to buy now?

Bell Potter has good things to say about this blue chip star.

Read more »

Scientists in a laboratory look at a computer screen with anticipation on their faces representing a potential change in the performance of ASX biotech shares in FY23
Healthcare Shares

Down 10% in a month, are CSL shares feeling the sting of a potential disruption?

Brokers are still bullish.

Read more »

One girl leapfrogs over her friend's back.
Healthcare Shares

Doubled in a year! Does this booming ASX share have another 24% upside?

Let's take a look.

Read more »